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Abstract
Objective: To explore the risk factors of distant brain failure (DBF) for patients with brain metastasis (BM) who
were treated with stereotactic radiotherapy alone and to group the patients on the basis of their risk levels.
Methods and Materials: We retrospectively analyzed 132 newly diagnosed BM patients who were treated with
stereotactic radiotherapy alone from May 2000 to April 2010. Kaplan-Meier and Cox proportional hazards regression
analyses were performed for univariate and multivariate analyses.
Results: The 1-year incidence rate of DBF was 44.7%, and the median DBF time (MDBFT) was 18 months. In
multivariate analysis, the risk factors of DBF were the number of BMs greater than 1 (p = 0.041), uncontrolled
extracranial disease (p = 0.005), interval time (IT) of less than 60 months between the diagnosis of primary tumor and
BM (p = 0.024), and total volume of BM was greater than 6 cc (p = 0.049). Each risk factor was assigned 1 score. The
median survival times for the patients with scores of 0-1, 2-3, and 4 were 31, 12, and 10 months, respectively, and the
corresponding MDBFTs were not reached, 13, and 3 months, respectively, (p < 0.001). The crude DBF incidence rates in
patients with scores of 0-1, 2-3, and 4 were 14.8%, 50.0%, and 76.9%, respectively, (p < 0.001).
Conclusions: The patients with scores of 0-1 had a lower risk of DBF than the patients with higher scores did, and
it may be reasonable to treat these patients with SRS alone and resort to whole-brain radiation therapy only for
salvage. The patients with a score of 4 had the highest risk of developing DBF after stereotactic radiotherapy alone,
these patients may be candidates for initial whole-brain radiation therapy or clinical trials. The patients with a score
of 2-3 had a moderate risk of developing DBF, SRT alone combined with close clinical monitoring would be the
optimal treatment regimen for such patients, and for those patients with difficulties in receiving close clinical
mornitoring, SRT combined with WBRT will be more suitable.
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Introduction
The initial treatment for newly diagnosed brain metasta-
sis (BM) is controversial. Before the invention of com-
puted tomography (CT), clinicians had no option but to
treat the whole brain in cases of BM. The Radiation
Therapy Oncology Group (RTOG) [1-4] conducted mul-
tiple trials from the 1970s to the 1990s, in which whole-
brain radiation therapy (WBRT) for BM was intensively
studied; the trials showed that the median survival time
(MST) for these patients with BM was only 3-6 months.
Since the 1980s, stereotactic radiotherapy (SRT) became
widely available, and there are more options for the treat-
ment of BM. Prospective clinical trials on SRT for BM
showed that the survival time of BM patients treated
with SRT alone was similar to or better than that of
patients treated with SRT+WBRT [5-7]. However,
w h e t h e rS R Ta l o n eo rS R T + W B R Ti st h eo p t i m a lr e g i -
men for BM patients is yet to be determined. The
researchers who are in favor of SRT as the sole initial
therapy claimed that WBRT could be avoided in BM
patients who initially underwent SRT and that the cogni-
tive function of the patients treated with SRS alone was
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any medium, provided the original work is properly cited.significantly better than that of the patients treated with
SRT+WBRT [5]. On the other hand, the researchers who
are in favor of SRT+WBRT as the initial therapy claimed
that although the survival times of the patients treated
with SRT alone are similar to those of the patients trea-
ted with SRT+WBRT, salvage treatment for new intra-
cranial lesions needs to be performed significantly more
often in the patients treated with SRT alone than in the
patients treated with SRT+WBRT.
BM patients are a heterogeneous group; they show
differences in number of BMs, total volume of BM,
extracranial disease state, interval between diagnosis of
the primary tumor diagnosis of and BM, Karnofsky per-
formance score (KPS), and histologic characteristics. In
some studies, these factors were defined as predictors of
DBF in patients treated with SRT alone [6,8-12].
Although several studies have included these factors in
the secondary analyses, few have attempted to specifi-
cally identify the variables that are the predictors of
DBF. Therefore, the objective of this study was to iden-
tify the risk factors of DBF in patients who were initially
treated with SRT alone for newly diagnosed BMs. These
variables may help clinicians classify these patients on
the basis of their risk of developing new intracranial
lesions, which in turn would help clinicians decide
whether to resort to WBRT for only salvage or to
include it in the initial therapy regimen.
Methods and Materials
Patient population
This study included 132 patients with newly diagnosed
BM who were treated with SRT alone by using the
Linac at the Department of Radiation Oncology, Cancer
Institute and Hospital, Chinese Academy of Medical
Sciences between May 2000 and April 2010. Cancer and
cerebral metastases were confirmed on the basis of his-
tologic analysis of the specimens obtained from extra-
cranial sites, and findings of magnetic resonance
imaging (MRI) of the brain, respectively. The demo-
graphic and clinical characteristics of the patients are
shown in Table 1.
Study variables
We reviewed the patients’ records and obtained data on
potential risk factor variables including histologic char-
acteristics, total number of metastases, total volume of
metastases, interval time (IT) between the diagnosis of
primary tumor and BM, KPS score, and the extracranial
disease state. Tumor volume was recorded on the basis
of the contouring required in SRT planning. Extracranial
Table 1 Patient characteristics
Parameters Total (n = 132) No DBF (n = 72) DBF (n = 60)
Sex (male %) 75 (56.8%) 47 (65.3%) 28 (46.7%)
Age (years) 57 (27-87) 58 (38-80) 57 (27-87)
No. of metastases 1 (1-6) 1 (1-4) 2 (1-6)
1 86 (65.2%) 57 (43.2%) 29 (22.0%)
> 1 46 (34.8%) 15 (11.4%) 31 (23.5%)
Total target volume (cc) 4.26 (0.10-57.84) 3.42 (0.23-57.84) 3.45 (0.10-45.47)
> 6 50 (37.9%) 22 (16.7%) 28 (21.2%)
≤ 6 82 (62.1%) 50 (37.9%) 32 (24.2%)
Extracranial disease
Progressive 91 (68.9%) 43 (32.6%) 48 (36.4%)
Absent or controlled 41 (31.1%) 29 (22.0%) 12 (9.1%)
IT (months) 12 (0-240) 12 (0-240) 13 (0-192)
≥ 60 20 (15.2%) 15 (11.4%) 5 (3.8%)
< 60 112 (84.8%) 57 (43.2%) 55 (41.7%)
KPS score 80 (40-90) 80 (40-90) 70 (50-90)
KPS = 70 45 (34.1%) 18 (13.6%) 27 (20.5%)
KPS ≠ 70 87 (65.9%) 54 (40.9%) 33 (25.0%)
Histologic characteristics
NSCLC 79 (59.8%) 45 (34.1%) 34 (25.8%)
Melanoma 5 (3.8%) 2 (1.5%) 3 (2.3%)
Breast cancer 15 (11.4%) 8 (6.1%) 7 (5.3%)
RCC 9 (6.8%) 6 (4.5%) 3 (2.3%)
Other 24 (18.2%) 11 (8.3%) 13 (9.8%)
IT, interval time; KPS, Karnofsky performance score; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma
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progressive.
SRT
The XSTPS V2.2 plan system (Creat company, China, May
1, 2000 to July 31, 2008) and BrainSCAN 5.31 plan system
(August 1, 2008 to April 30, 2010) were used for SRT in
the patients. All the patients were treated as outpatients.
The treatment plan was formulated by a radiation oncolo-
gist and a radiation physicist. Delineation of gross tumor
volume (GTV) was identified using CT and MRI fusion
images. To determine the planning target volume (PTV),
we used a margin of 2 mm in all directions around the
GTV, and 80-90% isodose enclosed the PTV. Dose fractio-
nation schemes were 20-30 Gy/1 f/1 d and 24-50 Gy/5-12
Gy/2-10 f. Fractionated radiation therapy was performed
daily or on alternate days, the median total dose was
30 Gy. The radiation dose was contingent on tumor
volume and location in the brain, and the SRT fractiona-
tion scheme was listed in table 2.
Follow-up
The first follow-up occurred at 1 month after stereotactic
radiation therapy, and follow-up was conducted at 2-3
months intervals thereafter. At each visit, a recent brain
MRI study was reviewed and compared with previous
MRI studies.
Statistical analysis
The overall survival time was calculated as the time
between SRT and death from any cause. For surviving
patients, they were censored at the date of the last follow-
up. The interval between the end of SRT and the first
occurrence of new intracranial lesions, which was deter-
mined by using MRI was defined as DBF time. If there was
no record of DBF, patients were censored at the date of
their last MRI. Kaplan-Meier and Cox proportional hazards
regression analyses were used for univariate and multivari-
ate analyses, respectively, for all possible risk factors asso-
ciated with DBF. The MST and median DBF time
(MDBFT) were calculated by using the Kaplan-Meier
analysis.
Result
During our study period, 109 patients died. Of the 23
surviving patients, 9 (39.1%) showed DBF. Fifty (45.9%)
of the 109 patients who died showed DBF. This differ-
ence was not statistically significant (p = 0.521). The
reasons of death were listed in table 3. There were 24
(22.0%) patients died of uncontrolled brain metastasis
for the whole group, And for the patients who suffered
from DBF, 19(35.8%) were died of uncontrolled brain
metastasis, but for the patients without DBF, only 6
(9.8%) died of uncontrolled brain metastasis. 44.7%. The
6-month and 1-year local control rate was 86.9% and
81.4%, separately.
The overall 1-year incidence rate of DBF was 44.7%.
Univariate analysis showed that the number of BM (p =
0.003), total target volume (p = 0.021), extracranial dis-
ease state (p = 0.003), interval between the diagnosis of
primary tumor and BM (p = 0.011), and KPS (p =
0.012) significantly affected the DBF incidence rate; the
differences in the histologic characteristics of the 2
groups were not statistically significant in the univariate
analysis (Table 4). All potential risk factors were ana-
lyzed in the multivariate analysis. Number of BMs (1 vs.
2 or more, p = 0.041), total target volume (≤ 6c cv s .>
6 cc, p = 0.049), extracranial disease state (absent or
stable vs. uncontrolled, p = 0.005), IT between the diag-
nosis of the primary tumor and BM (≥ 60 months vs. <
60 months, p = 0.024) were independent risk factors for
DBF; the differences in KPS and histologic characteris-
tics of the 2 groups were not statistically significant
(Table 5).
Each risk factor with a significance value of p ≤ 0.05
in the multivariate proportional hazard model was
assigned a score of 1. The MSTs for patients with scores
of 0-1, 2-3, and 4 were 31, 12, and 10 months, respec-
tively (Figure 1). The corresponding MDBFTs after the
initial SRT were not reached, 13 and 3 months, respec-
tively (p < 0.001) (Figure 2). The median follow-up time
for the whole group was 12 months, and that for the
patients with scores of 0-1, 2-3, and 4 were 17.5, 12,
and 10 months, respectively. During the follow-up, the
crude DBF incidence rates for patients with scores of 0-
Table 2 SRT fractionation scheme
Volume of single lesion Dose fractionation schemes Number of lesions
≤ 3 cc 20~30 Gy/1f/1d
45 Gy/5 Gy/9f/11d(2 lesions of brain stem)
78(35.3%)
3 cc~9 cc 24 Gy/12 Gy/2f/2d
30~36 Gy/10~12 Gy/3f/3d
40 Gy/10 Gy/4f/4-7d
40~45 Gy/8~9 Gy/5f/5-7d
120(54.3%)
≥ 9 cc 42 Gy/6 Gy/7f/9d
45 Gy/5 Gy/9f/11d
50 Gy/5 Gy/10f/12d
23(10.4%)
Total: 221(100%)
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(p < 0.001).
Discussion
Published literature showed that about 20-40% of the BM
patients died of intracranial diseases [1,7,13,14], and 60-
80% died because of progression of the extracranial dis-
ease or other reasons. With the development of cancer
therapy, both intracranial and extracranial diseases were
controlled better than they were earlier: the overall survi-
val time of BM patients was prolonged, and more impor-
tantly, the quality of life of these patients improved.
Thus far, almost all the clinical trials have shown that
the MST of BM patients treated with SRT alone is simi-
lar to that of the patients treated with SRT+WBRT. The
point at issue is the influence of WBRT on the quality
of life or neurocognitive functions of these patients.
In 2007, Aoyama [15] et al. reported how the omission
of WBRT affected the neurocognitive function of patients
with 1-4 BMs who were previously treated with SRT.
Neurocognitive function was assessed by using the Mini-
Mental State Examination (MMSE), which was criticized
for its low sensitivity [16]. The DBF incidence rate in the
patients treated with SRT+WBRT group was much lower
than that in the patients treated with SRT alone. The
average intervals before deterioration of neurocognitive
function in patients treated with WBRT+SRT and SRT
alone were 16.5 and 7.6 months, respectively, (p = 0.05).
However, the neurocognitive function preservation rate,
determined on the basis of the MMSE score, was not sig-
nificantly different between the 2 patient groups. The
patients treated with WBRT+SRT showed a more contin-
uous decrease in their MMSE scores than the patients
initially treated with SRT. The long-term adverse effects
of WBRT on neurocognitive functions may not be negli-
g i b l e .I n2 0 0 9 ,C h a n ge ta l .[ 5 ]r e p o r t e dar a n d o m i z e d
clinical trial in which they tested whether the advantages
of performing WBRT after SRT for the control of brain
tumors outweighs the potential neurocognitive risks of
WBRT. Chang et al. evaluated the neurocognitive
Table 4 Results of the univariate analysis
Parameter Number of patients MDBFT (months) 95% confidence interval p value
No. of metastases 0.003
1 86 (65.2%) 54 –
> 1 46 (34.8%) 8 2.0-14.1
Total target volume (cc) 0.021
> 6 50 (37.9%) 10 4.7-15.3
≤ 6 82 (62.1%) 21 11.8-30.2
Extracranial disease 0.003
progressive 91 (68.9%) 11 6.3-15.7
absent or controlled 41 (31.1%) Not reach –
IT(months) 0.011
≥ 60 20 (15.2%) Not reach –
< 60 112 (84.8%) 12 7.6-16.5
KPS score 0.012
KPS = 70 45 (34.1%) 10 3.3-16.7
KPS ≠ 70 87 (65.9%) 21 9.5-32.5
Histologic characteristics 0.762
Melanoma 5 (3.8%) 18 0-41.4
Others 127 (96.2) 15 7.7-23.3
Risk factor scores < 0.001
0-1 27 (20.5%) Not reach –
2-3 92 (69.7%) 13 8.4-17.6
4 13 (9.8%) 3 2.0-4.0
IT, interval time; KPS, Karnofsky performance score
Table 3 Reasons of death
Reason of death The whole group n = 109 DBF n = 50 NO DBF n = 59
Uncontrolled brain metastasis 24(22.0%) 18(36.0%) 6(10.2%)
Progression of the extracranial disease 71(65.1%) 25(50.0%) 46(77.9%)
Non-cancer related reasons 9(8.3%) 4(8.0%) 5(8.5%)
Unknown reasons 5(4.6%) 3(6.0%) 2(3.4%)
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Revised (HVLT-R), which is more precise than the
MMSE. The recurrence rate of intracranial lesion was
higher in the patients treated with SRT alone than in the
patients treated with WBRT+SRT. However, the risk of a
significant decline in learning and memory function after
4 months was lower in the patients treated with SRT
alone than that in the patients treated with WBRT+SRT
after effective salvage treatment. As a result, Chang et al.
recommended the use of a combination of SRT and close
clinical monitoring for the initial treatment of newly
diagnosed BM. However, in our trial, salvage treatment
for the 2 groups was not the same; the treatment was
more aggressive for the patients treated with SRT alone;
therefore, some authors questioned the reliability of these
results. The European Organization for Research and
Treatment of Cancer (EORTC) 22952-26001 [7] study
was a randomized phase III trial on patients with 1-3
BMs. Patients were randomly selected for treatment with
SRT alone or SRT+WBRT; the primary end point was
the functional survival time. Although this trial did not
evaluate the neurocognitive functions of the 2 groups,
the functional survival time of the 2 groups was similar.
From the above literatures, we can found that WBRT
can improve the intracranial tumor control rate and
decrease the risk of DBF, but it cannot increase the
overall survival time of BM patients; and we can not
find any evidence to indicate that a better intracranial
tumor control rate can lead to a better quality of life for
these patients. Therefore, it is important to determine
which patients are at a high risk of DBF after SRT
alone; WBRT would be necessary for these patients.
According to the published articles, the possible risk
factors of DBF include number of BMs [6,8,10,12], total
Figure 1 Median survival time classified according to risk factor scores.
Table 5 Results of the multivariate analysis
Parameter p value Hazard ratio 95% confidence interval for Hazard ratio
No. of metastases
> 1 vs. 1
0.041 1.77 1.02-3.05
Total target volume (cc)
≤ 6 vs. > 6
0.049 0.59 0.35-0.99
Extracranial disease
progressive vs.
absent or controlled
0.005 2.55 1.33-4.87
IT (months)
≥ 60 vs. < 60
0.024 0.34 0.14-0.87
KPS score
≠70 vs. = 70
0.140 0.66 0.39-1.14
Histologic characteristics
Melanoma vs. Others
0.416 1.66 0.49-5.58
IT, interval time; KPS, Karnofsky performance score
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interval between the diagnosis of the primary tumor and
BM [10], KPS [6], and histologic characteristics [8]. The
results of our multivariate analysis suggest that the
number of BM, total target volume, extracranial disease
state, and the interval between the diagnosis of the pri-
mary tumor and BM were independent risk factors of
DBF; this finding is similar to those of the above-men-
tioned articles. The intergroup differences in KPS in the
univariate analysis were statistically significant, but those
in the multivariate analysis were not. Therefore, KPS
was not considered an independent risk factor for DBF.
The differences in histologic characteristics of the 2
groups in both univariate and multivariate analyses were
not significantly different; this finding could be attribu-
table to the small number of patients with small cell
lung cancer (SCLC) and melanoma.
Thus far, several studies have attempted to identify
predictors of DBF (or metachronous BM) in secondary
analyses, but only Sawrie et al. [8] specifically identified
these variables in the primary analyses. In that study
BM patients were divided into 2 subgroups: the low-risk
subgroup (without risk factor) and the high-risk sub-
group (with risk factors) (there was no moderate risk
subgroup, which was different from our results). In our
study, BM patients were divided into 3 subgroups on
the basis of the number of the risk factors: patients with
a score of 0-1, patients with a score of 2-3, and patients
with a score of 4. The intergroup differences in both
MDBFT (not reached, 15, and 3 months; p < 0.001) and
crude incidence rates of DBF (14.8%, 50.0%, and 76.9%;
p < 0.001) were statistically significant.
Our data suggested that patients with a score of 0-1
had a low risk of developing DBF and that it may be
reasonable to treat these patients with SRT alone. These
patients would still have the option of undergoing addi-
tional SRT or WBRT as salvage therapy, depending on
the nature and severity of any disease progression. The
patients with a score of 4 were at the highest risk to of
developing DBF, such as these patients 4 scores sub-
group, may be better candidates for WBRT as a part of
their initial treatment or for enrollment into clinical
trials. Fifty percent of the patients with a score of 2-3
scores subgroup would develop DBF during their life
span. Therefore, we recommend that SRT alone with
close clinical monitoring be performed as the initial
treatment in these patients in consideration of the pal-
liative intent of BM therapy. However, if in cases in
which close clinical monitoring cannot be performed,
then combined therapy of SRT+WBRT for BM should
be performed as initial treatment. Our treatment recom-
mendations were summarized in table 6.
However, the results of this study are subject to any of
the biases inherent in a retrospective analysis, and our
risk stratification requires prospective validation. More-
over, since most of the patients included in our study
had 1-3 BMs and only 6.8% of the patients had more
than 3 lesions, it is unclear whether our findings are
Figure 2 Median distant brain failure time classified according to risk factor scores.
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metastasis.
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Table 6 Treatment recommendations by risk level
Risk factor score summation Crude DBF rate Treatment recommendations
0~1 14.8%, SRT as initial treatment and WBRT ± SRT as salvage treatment for DBF
2~3 50.0%, SRT + close clinical monitoring as initial treatment;
if close clinical monitoring is impossible, then WBRT+SRT as initial treatment
4 76.9% WBRT+SRT as initial treatmentt
Risk factors include number of BMs > 1, total target volume > 6 cc, uncontrolled extracranial disease and interval time between the diagnosis of the primary
tumor and BM < 60 months, and each risk factor was assigned a score of 1
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